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Background: Intraoperative radiofrequency ablation (IRFA) of liver metastases can be used to treat
patients with complex tumours that are unsuitable for parenchymal resection alone. This systematic
review assesses the frequency, patterns and severity of complications associated with this procedure.
Methods: We carried out a bibliographic search on MEDLINE focused on IRFA for liver metastases,
excluding hepatocarcinomas, and on intraoperative use, excluding percutaneous application.
Results: Thirty papers published between 1999 and 2007 were analysed. They covered a total of 2822
patients and 1755 IRFA procedures. The indications and techniques for IRFA differ from those for
percutaneous treatment, as do associated results and complications. Specific complications associated
with IRFA, such as liver abscesses, biliary stenoses and vascular thromboses, are directly correlated with
the indications and associated procedures. Published results should be interpreted with caution as IRFA
can be used alone or combined with parenchymal resection.
Conclusions: Specific complications related to IRFA are rare, especially for lesions of <35 mm in size
located far from a main biliary duct, when additional septic procedures are not used. A lesion-by-lesion
approach based on the benefit : risk ratio should therefore be used in the process of making surgical
decisions. Combining resection with IRFA leads to higher morbidity, especially in difficult patients with
numerous bilateral lesions, but may be necessary to achieve R0 (microscopically negative margins)
outcomes.
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Introduction
Intraoperative radiofrequency ablation (IRFA) of liver metastases
was first reported by Curley et al.1 in 1999 and Elias et al.2 in 2000.
Promising initial results appeared to herald a new era in modern
liver surgery.3 However, unexpectedly, most of the teams who
launched this technique in the late 1990s have since decided to
forego IRFA4–7 because of disagreement between hepatopancreato-
biliary surgeons and radiologists. Radiologists have challenged the
treatment of liver metastases by parenchymal resection only and
proposed using percutaneous RFA (PRFA) as a minimally invasive
alternative. In response, surgeons have simply decided to sacrifice
both IRFA and PRFA at the same time. The results of PRFA are
inferior to those of IRFA, especially in terms of local recurrence
rates, and the presentation of combined outcomes for both tech-
niques resulted in the exclusion of both.8 In the same manner,
Abdalla et al.4 compared RFA with surgery, but allocated the
easiest-to-treat lesions with wide margins to resection and the
difficult-to-treat lesions to ablation, with unsurprising results:
RFA, even via the intraoperative route, offered inferior results and
hence its abandonment was recommended. Subsequently, and sur-
prisingly, some published material9 declared the absence of need
for multicentre prospective studies, which, with less biased meth-
odology,might have produced different results. Curiously enough,
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in this same paper,Curley acknowledged that he continued to treat
almost 10% of his patients with IRFA, indicating that perhaps the
technique should not be discarded just yet.
In the last decade, efforts have focusedmostly on learning about
this treatment and most reports have been retrospective and have
originated from expert centres. Data from two prospective studies,
the CLOCC (Chemotherapy + Local Ablation Versus Chemo-
therapy for unresectable liver metastasis) Study10 and the
ARF2003 Study,11 are to be published in 2010. Preliminary results
from these are positive, despite a 22% lack of enrolment in the
CLOCC Study. As a consequence, IRFA may enter an era of reju-
venation, in which its place in the surgical armamentarium is
reserved on the strength of scientific evidence. Before we can
embrace this new era, it is necessary to analyse the complications
associated with IRFA by examining the available literature, mainly
to explain how the best benefit : risk ratio can be determined for
an individual patient. This review of the available IRFA literature
covers 30 articles and identifies the frequencies, patterns and
severity of complications associated with this procedure.
Materials and methods
Search strategy and selection criteria
A bibliographic search was conducted on MEDLINE. Mesh
requests were: ‘liver neoplasms’ ‘catheter ablation’, ‘laparotomy’
and ‘hepatectomy’. Additional keywords were added: ‘intra-
operative’, ‘coeliotomy’ and ‘open’. The exact request was:
(‘catheter ablation’[Mesh] AND ‘liver neoplasms’[Mesh]) AND
(‘hepatectomy’[Mesh] OR ‘laparotomy’[Mesh] OR ‘intraopera-
tive’ OR ‘open’ OR ‘coeliotomy’).
The search was run in December 2008. Articles dealing exclu-
sively with PRFA or with hepatocellular carcinoma (HCC) were
excluded. Articles in all languages were accepted. Papers reporting
complications of IRFA were selected and data were collected in a
database (Microsoft Access 2003©). The following variables were
recorded for each article.
Article characteristics
1 Title.
2 First author.
3 Year of publication.
4 Country of origin.
Population to be studied
1 Number of patients.
2 Number of IRFA procedures.
3 Average age of patients.
4 Frequency of cirrhotic patients.
Description of the diseases to be treated
1 Ratio of HCCs : metastases treated.
2 Size and number of lesions.
Description of complications
1 Mortality.
2 Liver failure.
3 Infections:
• intra- and perihepatic abscesses;
• peritonitis, and
• abdominal wall abscesses.
4 Vascular complications:
• haemorrhages and vascular injuries;
• haematomas, and
• portal thromboses.
5 Biliary complications:
• bile collections;
• bile leakages;
• biliary stenoses, and
• cholangitis.
6 Collateral lesions (or visceral lesions):
• burns (biliary structures, digestive tract, diaphragm . . . );
• injuries, and
• pneumothorax.
7 Skin burns.
8 Pleural collections.
The terminology used was that recommended by the Inter-
ventional Radiology Technology Assessment Committee
and the International Working Group on Image-Guided
Tumour Ablation12 updated by the Society of Interventional
Radiology.13
Results
Our search retrieved 493 articles (Fig. 1). After exclusions
for percutaneous-only treatment and HCCs, we selected 30
papers published between 1999 and 2007 (Table 1).1,2,14–41
These papers covered a total of 2822 patients and 1755
IRFA procedures. In 961 of these procedures (54.8%), the
lesions were treated by resection combined with IRFA.
Complications were reported for series varying from five
to 382 procedures. Only one series was a prospective multicentre
study.25 Eighteen articles were based on fewer than 50
patients.
In five papers15,20,27,31,37 involving 450 patients and 343 IRFA
procedures, IRFA was always combined with resection. In five
other papers16,21,28,33,35 (226 patients, 107 IRFA), no resections
were performed in combination with IRFA. Only four papers
reported frequencies of patients with cirrhosis (varying
from 13.1% to 33.3%) and 22 articles reported frequen-
cies of HCC, varying from none to 44.4%. The average
lesion size (reported in 13 articles) ranged from 13 mm to
56 mm. Thirteen articles specified the mean number of
lesions to be treated, which ranged from one to 6.2 lesions per
patient.
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Potentially relevant publications
identified and screened for retrieval
n = 493 
Publications with usable information
n = 30 
Excluded n = 463
- RFA by percutaneous route only
- HCC only
- No information about complications 
Figure 1 Details of methods used to select articles for the review of complications after intraoperative radiofrequency ablation of liver
metastases. RFA, radiofrequency ablation; HCC, hepatocellular carcinoma
Table 1 Publications retrieved after a literature search for articles on intraoperative radiofrequency ablation of liver metastases
Author(s) IRFA, n HCC Combined
resection + IRFA
Mortality Morbidity
Pearson et al. (1999)32 92 36.9% 19.5% 0% 3.3%
Curley et al. (1999)1 92 23.9% 19.5% 0% 3.2%
Jiao et al. (1999)26 30 20% 43.3% 3.3% 10%
Wood et al. (2000)41 39 – 51.2% 5% 5%
Elias et al. (2000)2 21 0% 80.9% 0% 47.6%
Wong et al. (2001)40 39 5% 48.7% 0% 20.5%
Risse et al. (2001)34 19 31.5% 52.6% 5.2% 26.3%
Stippel et al. (2002)37 23 0% 100% 0% 17.3%
Stella et al. (2002)36 21 19% 61.9% 0% 14.3%
Choy et al. (2002)17 12 – 75% 0% 33.3%
Pawlik et al. (2003)31 172 2.9% 100% 2.3% 19.8%
de Baere et al. (2003)19 124 – 95.1% 2.4% 9.6%
Bleicher et al. (2003)15 66 – 100% 0% 12.1%
Oshowo et al. (2003)30 16 0% 62.5% 0% 12.5%
Curley et al. (2004)18 382 14.6% 48.1% 0.52% 8.6%
Poon et al. (2004)33 56 – 0% 1.8% 16%
Tepel et al. (2004)38 26 – 42.3% 0% 27%
Basdanis et al. (2004)14 18 0% 11.1% 0% 0%
Jansen et al. (2005)25 108 10.6% 34.2% 1.8% 20.3%
Elias et al. (2005)20 63 0% 100% 0% 27%
Navarra et al. (2005)29 53 0% 22.6% 1.8% 14%
Ritz et al. (2006)35 6 0% 0% 0% 0%
Hildebrand et al. (2006)22 68 5.8% 52.9% 2.9% 7.3%
Hildebrand et al. (2006)23 64 – 56.3% 0% 12.5%
Chhabra et al. (2006)16 27 44.4% 0% 0% 3.7%
Low et al. (2006)28 13 – 0% 0% 0%
Gomez et al. (2006)21 5 – 0% 0% 0%
Topal et al. (2007)39 49 20.4% 24.5% 2% 34.7%
Hubert et al. (2007)24 32 12.5% 72% 0% 18%
Kornprat et al. (2007)27 19 0% 100% 5.2% 31.5%
IRFA, intraoperative radiofrequency ablation; HCC, hepatocellular carcinoma
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Frequency of complications
Table 2 reports mortality and morbidity rates, as well as frequen-
cies and types of complications, depending on whether or not
IRFA was associated with resection. Table 3 presents the same
results according to the size of the series.
Mortality
A total of 21 deaths were reported in 11 series,18,19,23,25–27,29,31,33,39,41
with overall mortality varying from 0% to 5.2%. Four deaths were
related to cirrhosis. Eleven occurred in patients undergoing resec-
tions, eight of which were major hepatectomies.
Causes of death are summarized in Fig. 2. Eight deaths were
related to liver failure,18,19,25,31,34,41 four of which were subsequent
to major hepatectomy with IRFA on the remnant liver for
bilobar disease.18,19,31,41 Five deaths were caused by myocardial
infarct;18,23,39,41 one of these related to a carcinoid crisis41 and
another to a haemorrhage.18 Four deaths resulted from portal
thrombosis,19,25,34 three of which occurred in cirrhotic
patients.19,34 One of these patients had been treated by IRFA
alone.34 Four deaths were related to septic complications; two of
these referred to pulmonary infections,26,31 one to infection of
the ascites25 and one to multiple deep abscesses.25 Lastly, three
deaths were reported after postoperative haemorrhaging;18,25,31
one was caused by liver failure after an intrahepatic haematoma
in a cirrhotic setting,25 one resulted from myocardial infarction
following a haemorrhage in a large metastasis treated by IRFA,18
and one patient was treated by major hepatectomy and two
IRFA sessions and died of cardiac arrest after postoperative
bleeding.31
Infections
Abdominal infections were reported in 49 patients in 21
series.9,15,17,18,20,22–27,29,31–34,36–38,40,41 Diagnosis of infection was
delayed by up to 5 months.25,41 Seventeen liver abscesses were
reported, of which one was fatal25 and 11 were related to IRFA.
Only one case of biliary digestive anastomosis was observed.22
Ten cases of perihepatic abscesses at resection sites were
reported. Twelve were following digestive system-associated
procedures. These abscesses were treated by percutaneous
drainage and antibiotics. One patient needed re-operation
and died from septic shock.25 Seven cases25,33,34,38,40 of wound
infection were reported; two were re-operated.25 Lastly, one
case of peritonitis after infection of the ascites was reported and
was fatal.25
Table 2 Morbidity rates in intraoperative radiofrequency ablation with or without resection
All series, mean
(min–max)
IRFA with resections,
mean (min–max)
IRFA alone, mean
(min–max)
Number of procedures, n 1755 343 107
Mortality 1.2% (0–5.2%) 1.5% (0–5.2%) 0.9% (0–1.8%)
Morbidity 13.6% (0–47.6%) 20.1% (12.1–31.5%) 9.3% (0–16%)
Wound infection 2.8% (0–13.4%) 3.5% (1.7–13.4%) 0.9% (0–1.8%)
Biliary complications 1.7% (0–9.5%) 3.8% (0–7.9%) 0.9% (0–1.8%)
Pleural effusion 1.4% (0–6.2%) 0.3% (0–0.6%) 1.9% (0–3.6%)
Liver failure 1.4% (0–14.2%) 2.6% (0–7.9%) 0.9% (0–1.8%)
Vascular complications 1.3% (0–5.3%) 0.6% (0–1.6%) 0.0% (0–0%)
Skin burns 0.5% (0–6.2%) 0.0% (0%) 0.9% (0–1.8%)
Collateral lesions 0.2% (0–1.5%) 0.6% (0–1.5%) 0.0% (0%)
Table 3 Morbidity rates in intraoperative radiofrequency ablation (IRFA) by size of series
All series, mean
(min–max)
Series with > 50 patients,
mean (min–max)
Series with  50 patients,
mean (min–max)
Number of procedures, n 1755 1340 415
Mortality 1.2% (0–5.2%) 1.1% (0–2.9%) 1.4% (0–5.2%)
Morbidity 13.6% (0–47.6%) 12.0% (2–27%) 18.8% (0–47.6%)
Wound infection 2.8% (0–13.4%) 2.7% (0–6.5%) 3.1% (0–13.4%)
Biliary complications 1.7% (0–9.5%) 1.3% (0–7.9%) 2.7% (0–9.5%)
Pleural effusion 1.4% (0–6.2%) 1.6% (0–6.2%) 0.7% (0–5.1%)
Liver failure 1.4% (0–14.2%) 1.3% (0–7.9%) 1.4% (0–14.2%)
Vascular complications 1.3% (0–5.3%) 1.4% (0–4.6%) 0.7% (0–5.3%)
Skin burns 0.5% (0–6.2%) 0.4% (0–4%) 0.7% (0–6.2%)
Collateral injuries 0.2% (0–1.5%) 0.3% (0–1.5%) 0.0% (0–0%)
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Biliary complications
Twenty-five early (30 postoperative days) and 14 delayed
(sometimes for >4 months18) biliary complications were
reported in 10 series.15,17,18,20,25,31,33,36,38,40 Twelve biliary leakages
occurred, 10 of which were early. Six occurred in resection com-
bined with IRFA. One early leakage was caused by a prophylactic
cholecystectomy, but two delayed leakages were associated with a
biliary stenosis.18 Fifteen intrahepatic bile collections were
described, one of which induced duodenal compression. One
article18 gave details of the treatment of eight biliomas: all eight
were drained percutaneously and two recurred after drain
clamping. Two were related to biliary stenoses and were treated
by intrahepatic stenting; the other six patients underwent endo-
scopic sphincterotomy. Eleven biliary stenoses associated with
jaundice and biliary dilatation were reported, of which five were
early. These were complicated by biliomas,18,25 biliary leakage25
and cholangitis.37 In their prospective study, Jansen et al.25 did
not observe a correlation between central or peripheric localiza-
tion of the tumour and the frequency of biliary complications,
by contrast with Curley et al.18 Elias et al.20 reported the effi-
ciency of biliary cooling in five patients, which prevented biliary
destruction in paraportal lesions.
Liver failure
Liver failure was reported in 24 patients in 11
articles2,15,18–20,25,29,31,33,34,41 and was fatal in eight patients. Fourteen
liver failures occurred after IRFA combined with major resec-
tion. Six liver failures occurred in cirrhotic patients; three of
these failures occurred after IRFA alone.18,34 Two liver failures
were subsequent to portal thrombosis.34
Vascular complications
Different types of vascular complication were described in 11
articles in a total of 22 patients.9,18,19,22,23,25,26,31,32,34,38 Associated pro-
cedures such as cholecystectomy or colectomy induced six haem-
orrhages, two of which were fatal31,25 and one required
re-operation after prophylactic cholecystectomy.38 Three haemor-
rhages from the needle track were treated during surgery18 by
compression. In three cirrhotic patients, haemorrhage occurred in
the necrosis induced by the IRFA; one patient died as a result.25
Treatment of two juxta-portal lesions induced haemorrhages
from arterial injuries.25,26 In one patient, an arterio-portal fistula
appeared in an area of necrosis 6 weeks later and was treated by a
transfemoral embolization.18 Similarly, a false aneurysm occurred
in one patient 6 months after IRFA and led to a haemorrhage.25
Five portal thromboses were reported,19,25,34 four of which were
complete and fatal. Three of these occurred in cirrhotic patients
treated with Pringle vascular occlusion.19,34
Skin burns
Eight dispersive pad skin burns were reported in four
articles.16,19,30,38 Skin burns occurred when RFA ran for >30 min on
high power and within large and multiple skin pads. One skin
burn occurred in a patient with bilateral hip prostheses.30 One
third-degree skin burn required surgical treatment.38
Visceral damage
Two instances of thermal gastric damage15,18 and one of acute
cholecystitis near the gallbladder25 were observed after IRFA
during surgery and were treated immediately.
Discussion
On the whole, the methodologies used in the articles retrieved by
the MEDLINE search were of a low scientific standard in terms of
evidence-based research. All but one reported retrospective expe-
riences and most involved only a single centre. The methodology
used to report and describe complications was not standardized
and mixed low and high grades of complication severity at differ-
ent durations of follow-up. Consequently, the data obtained
cannot be compared with those reported in studies that define
complications according to classifications such as that described
by Dindo et al.43 In addition, the populations studied were hetero-
geneous and it is thus impossible to calculate a confidence interval
n = 5 n = 8 n = 3 n = 5 n = 4
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Figure 2 Causes of death reported in the literature after intraoperative radiofrequency ablation of liver metastases
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for the means. Nevertheless, the different types of complication
reported are relatively similar across studies, which allows us to
assume a common general profile of the morbidity associated
with this technique.
Comparison with PRFA
Percutaneous RFA is a recommended treatment for HCC in cir-
rhotic patients. This procedure differs from IRFA in terms of
indications, techniques, results and morbidity. Table 4 summa-
rizes the different morbidities associated with IRFA and PRFA.
Results for PRFA were extracted from the literature review con-
ducted by Mulier et al., which reported 3670 RFA procedures,
2898 (78.9%) of which were PRFAs.44 Mortality and morbidity
rates after PRFA were lower than after IRFA (0.5% and 8.9% vs.
1.2% and 13.6%, respectively) when all patients receiving IRFA
were considered. However, when mortality and morbidity rates in
patients who received PRFA were compared with those in patients
who received only IRFA, thus excluding the effects of surgery,
mortality and morbidity rates were similar (0.5% and 8.9% vs.
0.9% and 9.3%, respectively).
The open procedure not only allows complete abdominal
exploration, but also enables visceral protection or immediate
reparation of visceral damage.However,Mulier et al. reported two
cases of gastric wall burns after IRFA.44 These complications were
diagnosed and treated successfully during the procedures. Only
one case of cholecystitis occurring after IRFA near the gallbladder
was reported. Prophylactic cholecystectomy may prevent this
complication, but specific vascular and biliary complications may
occur. As a result, systematic prophylactic cholecystectomy cannot
be recommended, but should be performed only for IRFA near the
gallbladder. Finally, specific complications, such as wound
infections, evisceration and abdominal dehiscence, are associated
with laparotomy.
Comparison with hepatectomy
The morbidity of hepatectomy depends on the extent and com-
plexity of the hepatic resection. Intraoperative RFA as a stand-
alone treatment is indicated for unresectable tumours in patients
in whommajor hepatectomy would leave a low level of functional
hepatic reserve. Mortality and morbidity rates in major hepatic
resection are 0–5% and 20–50%, respectively.45 Rates of liver
failure after major hepatectomy preceded by portal embolization
are 4–10%46,47 vs. 2.6% after IRFA combined with hepatic resec-
tion. Pawlik et al. reported mortality of 2.3% and morbidity of
19.8% in patients treated by resection and combined IRFA, and
estimate their results to be comparable with those of resection
alone.31 Morbidity rates after major hepatic resection and IRFA
combined with hepatic resection are comparable, even if IRFA is
indicated in tumours unresectable by hepatectomy alone.48
Table 5 summarizes differences in morbidity in patients undergo-
ing hepatectomy alone and hepatectomy combined with IRFA,
illustrating the great similarity between the techniques.
Specific complications of IRFA
Some complications are specific to RFA and thus can also be
induced by IRFA. Hepatic abscesses are caused by infection of the
necrotic tissue in the RFA site. They appear after an asymptomatic
period ranging from 8 days to 5 months.19,41,49 Imaging examina-
tions detect a lot of gas in the necrotic zone, which indicates an
abscess. However, the presence of a low quantity of gas is usual in
the necrotic zone during the month after RFA.50 Despite the fact
that, in our experience, an additional septic procedure such as
colectomy has a major role in the occurrence of such a complica-
tion, this has never been reported in the literature. It may be that
special prophylaxis antibiotics are indicated in such cases. Diabe-
tes mellitus and bilioenteric anastomosis are recognized risk
factors for hepatic abscess after liver ablation procedures and the
risk for abscess is estimated to be 40–50% in the presence of
bilioenteric anastomosis.19,51 Biliary colonizations (antecedents of
sphincterotomy, biliary stent, biliary stenoses, etc.) are other pos-
sible risk factors.44 Such abscesses should be treated by antibiotics
and percutaneous drainage, and sometimes by re-operation. Only
symptomatic biliary leakage such as infection or bowel compres-
sion should be treated by percutaneous drainage. In cases of asso-
Table 4 Comparison of morbidity rates in intraoperative radiofrequency ablation (IRFA) and percutaneous radiofrequency ablation (PRFA)
IRFA, mean (min–max) IRFA without resection,
mean (min–max)
PRFA, meana
Number of procedures, n 1755 107 3670
Mortality 1.2% (0–5.2%) 0.9% (0–1.8%) 0.5%
Morbidity 13.6% (0–47.6%) 9.3% (0–16%) 8.9%
Wound infection 2.8% (0–13.4%) 0.9% (0–1.8%) 1.1%
Biliary complications 1.7% (0–9.5%) 0.9% (0–1.8%) 1.0%
Liver failure 1.4% (0–14.2%) 0.9% (0–1.8%) 0.8%
Vascular complications 1.3% (0–5.3%) 0.0% (0–0%) 2.2%
Skin burns 0.5% (0–6.2%) 0.9% (0–1.8%) 0.6%
Visceral damage 0.2% (0–1.5%) 0.0% (0–0%) 0.5%
aResults of PRFA were extracted from the review by Mulier et al.44 Minimum and maximum data were not available for PRFA
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ciated biliary stenosis, intrahepatic stenting or endoscopic
sphincterotomy should be considered.
Biliary stenoses appear after the fibrous healing of biliary tract
thermal damage. They are diagnosed by imaging survey. Many of
these biliary stenoses are asymptomatic and do not require treat-
ment.52 Only biliary stenoses that occur near the major biliary
tract after RFA are symptomatic18,44 and can be treated by intra-
hepatic stenting or endoscopic sphincterotomy. Vascular occlu-
sions do not affect the frequency of biliary complications,
although experimental studies have suggested that vessels protect
the biliary tract by a ‘heat sink’ effect.53 Biliary refrigeration may
protect against biliary complications, but the oncological impact
remains to be evaluated.54
Intraoperative bleeding from the needle track can be treated
during surgery by manual compression. Postoperative haemor-
rhages sometimes require emergency re-operation or transfemo-
ral embolization, and may lead to death if care is not immediately
possible.
Vascular thromboses after IRFA are caused by thermal endot-
helial damage. Experimental studies suggest that vascular occlu-
sion increases the risk for vascular thrombosis, especially when the
distance is <5 mm.55 Mulier et al. confirmed this hypothesis in
their literature review.44 Portal thromboses are more frequent in
cirrhotic patients andmay be complicated by liver failure and fatal
issue.19 Thrombosis of veins of <3 mm in diameter is common
after IRFA. It is asymptomatic and spontaneous regression is often
observed after 2 months.19
Skin burns occur when the dispersion surface is inadequate
for the radiofrequency power. Goldberg et al. recommend that
multiple (e.g. four) large dispersive pads should be placed at
equal distances of 50 cm from the RFA site to prevent skin
burns.56
Conclusions
The past 10 years have represented a period of learning for sur-
geons who deal with liver metastases with the aim of treatingmore
patients by combining IRFA with resection. The benefit : risk ratio
is nowwell known and surgeons have access to the knowledge they
need to make more informed choices about whether to resect,
ablate or renounce treatment on a lesion-by-lesion basis. Surgeons
who are skilled in intraoperative ultrasound diagnosis and guid-
ance are now not only able to choose whether or not to perform
surgery, but are also able to perform IRFA and do not need to
involve a radiologist.
Specific complications related to IRFA are rare, especially if the
lesion is <35 mm in diameter and is located far from a main
biliary duct and no additional septic procedures are used. The
surgeon can decide to ablate a lesion in a more difficult situation,
but this carries greater risk. Combining resection with IRFA leads
to higher morbidity, especially in difficult patients with numerous
bilateral lesions, but this may be necessary to achieve R0 (micro-
scopically negative) resection margins. The final results of the
CLOCC Trial and the ARF2003 Study will shortly become avail-
able and will help to define the proper place of IRFA in the surgical
armamentarium.
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